Details of the Drug

General Information of Drug (ID: DMLUO5K)

Drug Name

BIIB094

Synonyms

ION859

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antisense oligonucleotide

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leucine-rich repeat kinase 2 (LRRK2)	TTK0FEA	LRRK2_HUMAN	Inhibitor	[2]
Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA)	TT1HI8U	LRRK2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03976349) A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Ionis